Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mehrdad Rezaee

Cardiovascular Disease San Jose, CA Medical Doctor

NPI 1629056692 CMS profile 28872

2030 Forest Ave, Suite 210, San Jose, CA 95128

Open in the dashboard

General payments

$10,382

282 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mehrdad Rezaee of San Jose, CA is reported in the CMS Open Payments database as having received $10,382 across 282 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,245 52
2024 General $3,538 67
2023 General $1,148 51
2022 General $1,384 22
2021 General $1,657 29
2020 General $275 12
2019 General $1,134 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mehrdad Rezaee
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Mehrdad Rezaee were reported at $1,245. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Mehrdad Rezaee Cardiovascular Disease median Middle half National median
2019 $1,134 $450 $127–$1,392 $163
2020 $275 $242 $77–$751 $114
2021 $1,657 $335 $101–$1,037 $132
2022 $1,384 $395 $121–$1,211 $149
2023 $1,148 $443 $136–$1,283 $160
2024 $3,538 $450 $136–$1,323 $164
2025 $1,245 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,691 51 payments
  2. Philips Electronics North America Corporation $968 24 payments
  3. Pfizer Inc. $793 42 payments
  4. E.R. Squibb & Sons, L.L.C. $595 36 payments
  5. Actelion Pharmaceuticals US, Inc. $579 23 payments
  6. Shockwave Medical, Inc $467 7 payments
  7. Novartis Pharmaceuticals Corporation $309 13 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $255 17 payments
  9. Abbott Laboratories $161 7 payments
  10. Novo Nordisk Inc $157 3 payments
  11. Other $1,405 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,841 254 payments
  2. Travel and Lodging $3,184 22 payments
  3. Education $233 5 payments
  4. Grant $123 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $3,122 27 payments
  2. CoreValve Evolut $1,030 9 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $706 37 payments
  4. OPSUMIT $554 23 payments
  5. UPTRAVI $464 14 payments
  6. ELIQUIS Cardiovascular $343 21 payments
  7. IGT D Coronary $326 6 payments
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $247 4 payments
  9. CAMZYOS $243 14 payments
  10. Micra $228 7 payments
  11. Other $4,203 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,869

Median for Cardiology: 2,533

Drug cost

$637,935

Median for Cardiology: $485,213

Branded share of claims

30.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 275 $370,407
Entresto Sacubitril/Valsartan Brand 90 $128,272
Xarelto Rivaroxaban Brand 45 $60,702
Repatha Sureclick Evolocumab Brand 24 $20,929
Multaq Dronedarone Hcl Brand 13 $20,333
Rosuvastatin Calcium Generic 203 $3,767
Nebivolol Hcl Generic 53 $3,674
Metoprolol Succinate Generic 268 $3,183
Losartan Potassium Generic 222 $2,878
Clopidogrel Clopidogrel Bisulfate Brand 199 $2,765

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$392,701

Of which drugs: $1,335

Medicare patients

518

Average age 79

Services billed

4,645

259 women, 259 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Diabetes 48%
Arthritis 43%
Chronic kidney disease 34%
Atrial fibrillation 33%
Heart failure 29%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) J0153 Office 45 1,991 $883
Infusion, normal saline solution, 250 cc J7050 Office 66 528 $272
Injection, regadenoson, 0.1 mg J2785 Office 19 73 $170

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $130
$130 275 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $100
$100 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $94
$94 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $88
$88 — —
NURTEC ODT
  • PFIZER INC. $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record